Psychonephrology 2022
DOI: 10.1007/978-3-030-84740-1_20
|View full text |Cite
|
Sign up to set email alerts
|

Gender Disparity and Women’s Health in Kidney Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2

Relationship

2
0

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 23 publications
0
2
0
Order By: Relevance
“… 4 Pregnancy is further challenging in women with kidney disease due to a higher risk of maternal and fetal morbidity and mortality, and drugs such as mycophenolate used to treat kidney disease such as lupus are contraindicated due to their teratogenicity risk. 5 , 6 …”
mentioning
confidence: 99%
“… 4 Pregnancy is further challenging in women with kidney disease due to a higher risk of maternal and fetal morbidity and mortality, and drugs such as mycophenolate used to treat kidney disease such as lupus are contraindicated due to their teratogenicity risk. 5 , 6 …”
mentioning
confidence: 99%
“…With kidney disease, there is a decrease in the clearance of prolactin, resulting in hyperproteinemia. Underlying comorbidities of autoimmune disease and use of immunosuppressive medications, like cyclophosphamide, to treat them also increase the risk of menstrual abnormalities (3). The reasons for the higher rates of menstrual abnormalities in women on peritoneal dialysis versus hemodialysis remain unclear, especially because patients on peritoneal dialysis likely have higher residual kidney function.…”
mentioning
confidence: 99%